Microbials for the production of monoclonal antibodies and antibody fragments

Trends in Biotechnology

Volumn 32, Issue 1, 2014, Pages 54-60

  Spadiut, Oliver ^a   Capone, Simona ^a   Krainer, Florian ^b   Glieder, Anton ^c   Herwig, Christoph ^a  

^a VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

^c AUSTRIAN CENTRE OF INDUSTRIAL BIOTECHNOLOGY   (Austria)

Author keywords

Antibody fragment; Mammalian cell; Microbial organism; Monoclonal antibody; Recombinant protein production

Indexed keywords

ANTIBODY FRAGMENT; BIOPHARMACEUTICAL PRODUCTS; MAMMALIAN CELLS; MICROBIAL ORGANISM; MONOCLONAL ANTIBODIES (MABS); PRODUCTION PROCESS; RECOMBINANT PROTEIN PRODUCTIONS; STRAIN ENGINEERING;

BINDING ENERGY; ESCHERICHIA COLI; MICROORGANISMS; SURFACE PLASMON RESONANCE; YEAST;

MONOCLONAL ANTIBODIES;

ANTIBODY; ANTIBODY FRAGMENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN BINDING; BACTERIAL STRAIN; BACTERIUM CULTURE; ESCHERICHIA COLI; FUNGAL STRAIN; FUNGUS CULTURE; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; GENETIC MANIPULATION; MAMMAL CELL; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SACCHAROMYCES CEREVISIAE;

ESCHERICHIA COLI; MAMMALIA; PICHIA PASTORIS; SACCHAROMYCES CEREVISIAE;

ANTIBODY FRAGMENT; MAMMALIAN CELL; MICROBIAL ORGANISM; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN PRODUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOENGINEERING; CELL LINE; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PICHIA; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 84890792810     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.10.002     Document Type: Review

References (80)

1. Lee J.Y., Bang D. Challenges in the chemical synthesis of average sized proteins: sequential vs. convergent ligation of multiple peptide fragments. Biopolymers 2010, 94:441-447.
2. Bolivar J.M., et al. Shine a light on immobilized enzymes: real-time sensing in solid supported biocatalysts. Trends Biotechnol. 2013, 31:194-203.
3. Chelliapan S., Sallis P.J. Removal of organic compound from pharmaceutical wastewater using advanced oxidation processes. J. Sci. Ind. Res. 2013, 72:248-254.
4. Walsh G. New biopharmaceuticals: a review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011. Process Development Forum 2012, BioPharm International. http://www.processdevelopmentforum.com/articles/new-biopharmaceuticals-a-review-of-new-biologic-drug-approvals-over-the-years-featuring-highlights-from-2010-and-2011/.
5. Butler M., Meneses-Acosta A. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl. Microbiol. Biotechnol. 2012, 96:885-894.
6. Berlec A., Strukelj B. Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. J. Ind. Microbiol. Biotechnol. 2013, 40:257-274.
7. de Marco A. Biotechnological applications of recombinant single-domain antibody fragments. Microb. Cell Fact. 2011, 10:44.
8. Li F., et al. Cell culture processes for monoclonal antibody production. MAbs 2010, 2:466-479.
9. Ahmad Z.A., et al. scFv antibody: principles and clinical application. Clin. Dev. Immunol. 2012, 10.1155/2012/980250.
10. Nelson A.L. Antibody fragments: hope and hype. MAbs 2010, 2:77-83.
11. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
12. Gorlani A., et al. Expression of VHHs in Saccharomyces cerevisiae. Methods Mol. Biol. 2012, 911:277-286.
13. Chee M.K., Haase S.B. New and redesigned pRS plasmid shuttle vectors for genetic manipulation of Saccharomyces cerevisiae. G3 (Bethesda) 2012, 2:515-526.
14. Park Y.N., et al. Application of the FLP/FRT system for conditional gene deletion in yeast Saccharomyces cerevisiae. Yeast 2011, 28:673-681.
15. Leite F.C., et al. Construction of integrative plasmids suitable for genetic modification of industrial strains of Saccharomyces cerevisiae. Plasmid 2013, 69:114-117.
16. Partow S., et al. Characterization of different promoters for designing a new expression vector in Saccharomyces cerevisiae. Yeast 2010, 27:955-964.
17. Maury J., et al. Reconstruction of a bacterial isoprenoid biosynthetic pathway in Saccharomyces cerevisiae. FEBS Lett. 2008, 582:4032-4038.
18. Joosten V., et al. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb. Cell Fact. 2003, 2:1.
19. Xu P., et al. Analysis of unfolded protein response during single-chain antibody expression in Saccharomyces cerevisiae reveals different roles for BiP and PDI in folding. Metab. Eng. 2005, 7:269-279.
20. Hou J., et al. Engineering of vesicle trafficking improves heterologous protein secretion in Saccharomyces cerevisiae. Metab. Eng. 2012, 14:120-127.
21. Idiris A., et al. Enhanced protein secretion from multiprotease-deficient fission yeast by modification of its vacuolar protein sorting pathway. Appl. Microbiol. Biotechnol. 2010, 85:667-677.
22. Hou J., et al. Heat shock response improves heterologous protein secretion in Saccharomyces cerevisiae. Appl. Microbiol. Biotechnol. 2013, 97:3559-3568.
23. Ferndahl C., et al. Increasing cell biomass in Saccharomyces cerevisiae increases recombinant protein yield: the use of a respiratory strain as a microbial cell factory. Microb. Cell Fact. 2010, 9:47.
24. Hamilton S.R., Gerngross T.U. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr. Opin. Biotechnol. 2007, 18:387-392.
25. Chiba Y., et al. Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae. J. Biol. Chem. 1998, 273:26298-26304.
26. Mattia, A. Diversa Corporation (2006) GRAS notification concerning BD16449 - phospholipase C enzyme preparation from Pichia pastoris, http://www.accessdata.fda.gov/scripts/fcn/gras_notices/grn000204.pdf.
27. Naatsaari L., et al. Deletion of the Pichia pastoris KU70 homologue facilitates platform strain generation for gene expression and synthetic biology. PLoS ONE 2012, 7:e39720.
28. Krainer F.W., et al. Recombinant protein expression in Pichia pastoris strains with an engineered methanol utilization pathway. Microb. Cell Fact. 2012, 11:22.
29. Delic M., et al. Repressible promoters - a novel tool to generate conditional mutants in Pichia pastoris. Microb. Cell Fact. 2013, 12:6.
30. Ruth C., et al. Variable production windows for porcine trypsinogen employing synthetic inducible promoter variants in Pichia pastoris. Syst. Synth. Biol. 2010, 4:181-191.
31. De Schutter K., et al. Genome sequence of the recombinant protein production host Pichia pastoris. Nat. Biotechnol. 2009, 27:561-566.
32. Mattanovich D., et al. Open access to sequence: browsing the Pichia pastoris genome. Microb. Cell Fact. 2009, 8:53.
33. Sohn S.B., et al. Genome-scale metabolic model of methylotrophic yeast Pichia pastoris and its use for in silico analysis of heterologous protein production. Biotechnol. J. 2010, 5:705-715.
34. Inan M., et al. Enhancement of protein secretion in Pichia pastoris by overexpression of protein disulfide isomerase. Biotechnol. Bioeng. 2006, 93:771-778.
35. Boehm T., et al. Disruption of the KEX1 gene in Pichia pastoris allows expression of full-length murine and human endostatin. Yeast 1999, 15:563-572.
36. Baumann K., et al. Protein trafficking, ergosterol biosynthesis and membrane physics impact recombinant protein secretion in Pichia pastoris. Microb. Cell Fact. 2011, 10:93.
37. Jahic M., et al. Modeling of growth and energy metabolism of Pichia pastoris producing a fusion protein. Bioprocess Biosyst. Eng. 2002, 24:385-393.
38. Hellwig S., et al. Analysis of single-chain antibody production in Pichia pastoris using on-line methanol control in fed-batch and mixed-feed fermentations. Biotechnol. Bioeng. 2001, 74:344-352.
39. Zalai D., et al. A dynamic fed batch strategy for a Pichia pastoris mixed feed system to increase process understanding. Biotechnol. Prog. 2012, 28:878-886.
40. Tegel H., et al. Enhancing the protein production levels in Escherichia coli with a strong promoter. FEBS J. 2011, 278:729-739.
41. Striedner G., et al. Plasmid-free T7-based Escherichia coli expression systems. Biotechnol. Bioeng. 2010, 105:786-794.
42. Mairhofer J., et al. Marker-free plasmids for gene therapeutic applications -Lack of antibiotic resistance gene substantially improves the manufacturing process. J. Biotechnol. 2010, 146:130-137.
43. Khodabakhsh F., et al. Comparison of the cytoplasmic and periplasmic production of reteplase in Escherichia coli. Prep. Biochem. Biotechnol. 2013, 43:613-623.
44. Sonoda H., et al. Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli. J. Biosci. Bioeng. 2011, 111:465-470.
45. Yuan J.J., et al. Protein transport across and into cell membranes in bacteria and archaea. Cell. Mol. Life Sci. 2010, 67:179-199.
46. Levy R., et al. Enhancement of antibody fragment secretion into the Escherichia coli periplasm by co-expression with the peptidyl prolyl isomerase, FkpA, in the cytoplasm. J. Immunol. Methods 2013, 394:10-21.
47. Huang C.J., et al. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J. Ind. Microbiol. Biotechnol. 2012, 39:383-399.
48. Jalalirad R. Production of antibody fragment (Fab) throughout Escherichia coli fed-batch fermentation process: changes in titre, location and form of product. Electron. J. Biotechnol. 2013, 16. 10.2225/vol16-issue3-fulltext-15.
49. Tao Y., et al. Metabolic engineering for acetate control in large scale fermentation. Methods Mol. Biol. 2012, 834:283-303.
50. Lara A.R., et al. Utility of an Escherichia coli strain engineered in the substrate uptake system for improved culture performance at high glucose and cell concentrations: an alternative to fed-batch cultures. Biotechnol. Bioeng. 2008, 99:893-901.
51. Sagmeister P., et al. Soft sensor assisted dynamic bioprocess control: efficient tools for bioprocess development. Chem. Eng. Sci. 2013, 96:190-198.
52. Jazini M., Herwig C. Effect of post-induction substrate oscillation on recombinant alkaline phosphatase production expressed in Escherichia coli. J. Biosci. Bioeng. 2011, 112:606-610.
53. Wechselberger P., et al. Model-based analysis on the extractability of information from data in dynamic fed-batch experiments. Biotechnol. Prog. 2013, 29:285-296.
54. Fisher A.C., et al. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Appl. Environ. Microbiol. 2011, 77:871-881.
55. Lizak C., et al. N-Linked glycosylation of antibody fragments in Escherichia coli. Bioconjug. Chem. 2011, 22:488-496.
56. van der Valk J., et al. Optimization of chemically defined cell culture media-replacing fetal bovine serum in mammalian in vitro methods. Toxicol. In Vitro 2010, 24:1053-1063.
57. Kim J.Y., et al. Proteomic understanding of intracellular responses of recombinant Chinese hamster ovary cells cultivated in serum-free medium supplemented with hydrolysates. Appl. Microbiol. Biotechnol. 2011, 89:1917-1928.
58. Ning D., et al. Production of recombinant humanized anti-HBsAg Fab fragment from Pichia pastoris by fermentation. J. Biochem. Mol. Biol. 2005, 38:294-299.
59. Wildt S., Gerngross T.U. The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 2005, 3:119-128.
60. Mille C., et al. Identification of a new family of genes involved in beta-1,2-mannosylation of glycans in Pichia pastoris and Candida albicans. J. Biol. Chem. 2008, 283:9724-9736.
61. Cregg J.M., et al. Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology 1993, 11:905-910.
62. Choi B.K., et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5022-5027.
63. Nett J.H., et al. A combinatorial genetic library approach to target heterologous glycosylation enzymes to the endoplasmic reticulum or the Golgi apparatus of Pichia pastoris. Yeast 2011, 28:237-252.
64. Hamilton S.R., et al. Production of complex human glycoproteins in yeast. Science 2003, 301:1244-1246.
65. Bernett M.J., et al. Engineering fully human monoclonal antibodies from murine variable regions. J. Mol. Biol. 2010, 396:1474-1490.
66. Callewaert N., et al. Use of HDEL-tagged Trichoderma reesei mannosyl oligosaccharide 1,2-alpha-D-mannosidase for N-glycan engineering in Pichia pastoris. FEBS Lett. 2001, 503:173-178.
67. 2-PP-Dol mannosyltransferase enzyme of P. pastoris. Glycobiology 2004, 14:399-407.
68. Jacobs P.P., et al. Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat. Protoc. 2009, 4:58-70.
69. Hamilton S.R., et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006, 313:1441-1443.
70. Hopkins D., et al. Elimination of beta-mannose glycan structures in Pichia pastoris. Glycobiology 2011, 21:1616-1626.
71. Choi B.K., et al. Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris. Appl. Microbiol. Biotechnol. 2012, 95:671-682.
72. Ye J., et al. Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnol. Prog. 2011, 27:1744-1750.
73. Campbell M., et al. Utilization of site-specific recombination for generating therapeutic protein producing cell lines. Mol. Biotechnol. 2010, 45:199-202.
74. Kameyama Y., et al. An accumulative site-specific gene integration system using Cre recombinase-mediated cassette exchange. Biotechnol. Bioeng. 2010, 105:1106-1114.
75. Lai T., et al. Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals 2013, 6:579-603.
76. Becker E., et al. Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. J. Biotechnol. 2010, 146:198-206.
77. Pfeffer M., et al. Intracellular interactome of secreted antibody Fab fragment in Pichia pastoris reveals its routes of secretion and degradation. Appl. Microbiol. Biotechnol. 2012, 93:2503-2512.
78. Lin-Cereghino G.P., et al. The effect of alpha-mating factor secretion signal mutations on recombinant protein expression in Pichia pastoris. Gene 2013, 519:311-317.
79. Lim S. An economic comparison of three cell culture techniques. BioPharm. Int. 2011, 24:54-60.
80. Dietzsch C., et al. A fast approach to determine a fed batch feeding profile for recombinant Pichia pastoris strains. Microb. Cell Fact. 2011, 10:85.